Pharmaniaga Berhad (KLSE:PHARMA)

Pharmaniaga Berhad Statistics

Total Valuation

KLSE:PHARMA has a market cap or net worth of MYR 1.67 billion. The enterprise value is 2.71 billion.

Market Cap	1.67B
Enterprise Value	2.71B

Important Dates

The next estimated earnings date is Wednesday, November 26, 2025.

Earnings Date	Nov 26, 2025
Ex-Dividend Date	n/a

Share Statistics

KLSE:PHARMA has 6.56 billion shares outstanding. The number of shares has increased by 0.56% in one year.

Current Share Class	6.56B
Shares Outstanding	6.56B
Shares Change (YoY)	+0.56%
Shares Change (QoQ)	n/a
Owned by Insiders (%)	1.11%
Owned by Institutions (%)	10.95%
Float	2.72B

Valuation Ratios

The trailing PE ratio is 2.68 and the forward PE ratio is 21.25.

PE Ratio	2.68
Forward PE	21.25
PS Ratio	0.42
PB Ratio	-14.14
P/TBV Ratio	n/a
P/FCF Ratio	16.46
P/OCF Ratio	13.09
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 6.89, with an EV/FCF ratio of 26.68.

EV / Earnings	19.80
EV / Sales	0.69
EV / EBITDA	6.89
EV / EBIT	10.04
EV / FCF	26.68

Financial Position

The company has a current ratio of 0.65

Current Ratio	0.65
Quick Ratio	0.36
Debt / Equity	n/a
Debt / EBITDA	2.96
Debt / FCF	11.46
Interest Coverage	3.81

Financial Efficiency

Return on Equity (ROE)	n/a
Return on Assets (ROA)	7.98%
Return on Invested Capital (ROIC)	16.82%
Return on Capital Employed (ROCE)	760.01%
Revenue Per Employee	1.12M
Profits Per Employee	39,097
Employee Count	3,502
Asset Turnover	1.86
Inventory Turnover	5.63

Taxes

In the past 12 months, KLSE:PHARMA has paid 66.51 million in taxes.

Income Tax	66.51M
Effective Tax Rate	32.48%

Stock Price Statistics

The stock price has decreased by -32.00% in the last 52 weeks. The beta is 1.01, so KLSE:PHARMA's price volatility has been similar to the market average.

Beta (5Y)	1.01
52-Week Price Change	-32.00%
50-Day Moving Average	0.24
200-Day Moving Average	0.25
Relative Strength Index (RSI)	46.74
Average Volume (20 Days)	54,677,195

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, KLSE:PHARMA had revenue of MYR 3.94 billion and earned 136.92 million in profits. Earnings per share was 0.10.

Revenue	3.94B
Gross Profit	550.48M
Operating Income	270.07M
Pretax Income	204.74M
Net Income	136.92M
EBITDA	382.96M
EBIT	270.07M
Earnings Per Share (EPS)	0.10

Balance Sheet

The company has 148.91 million in cash and 1.16 billion in debt, giving a net cash position of -1.02 billion or -0.15 per share.

Cash & Cash Equivalents	148.91M
Total Debt	1.16B
Net Cash	-1.02B
Net Cash Per Share	-0.15
Equity (Book Value)	-118.29M
Book Value Per Share	-0.10
Working Capital	-746.28M

Cash Flow

In the last 12 months, operating cash flow was 127.75 million and capital expenditures -26.14 million, giving a free cash flow of 101.61 million.

Operating Cash Flow	127.75M
Capital Expenditures	-26.14M
Free Cash Flow	101.61M
FCF Per Share	0.02

Margins

Gross margin is 13.98%, with operating and profit margins of 6.86% and 3.48%.

Gross Margin	13.98%
Operating Margin	6.86%
Pretax Margin	5.20%
Profit Margin	3.48%
EBITDA Margin	9.72%
EBIT Margin	6.86%
FCF Margin	2.58%

Dividends & Yields

KLSE:PHARMA does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-0.56%
Shareholder Yield	-0.56%
Earnings Yield	8.19%
FCF Yield	6.08%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number	n/a
Graham Upside	n/a

Stock Splits

The last stock split was on July 5, 2021. It was a forward split with a ratio of 5.

Last Split Date	Jul 5, 2021
Split Type	Forward
Split Ratio	5

Scores

KLSE:PHARMA has an Altman Z-Score of 1.67 and a Piotroski F-Score of 7. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	1.67
Piotroski F-Score	7